专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US5648240A MHC II analog from Staphylococcus aureus 失效
标题翻译：来自金黄色葡萄球菌的MHC II类似物
公开(公告)号：US5648240A
公开(公告)日：1997-07-15
申请号：US248021
申请日：1994-05-24
申请人： Magnus Hook , Klas Jonsson , Joseph M. Patti , Sivashankarappa Gurusiddappa
发明人： Magnus Hook , Klas Jonsson , Joseph M. Patti , Sivashankarappa Gurusiddappa
IPC分类号： A61K39/00 , C07K14/31 , C12N15/31 , A61K39/085
CPC分类号： C07K14/31 , A61K39/00 , Y10S530/825
摘要： Staphylococcus aureus can bind a number of different extracellular matrix proteins. Recent studies have shown that one particular Staphylococcus protein has the capacity of binding several different matrix proteins. The gene encoding this staphylococcal protein has been cloned and sequenced and the nucleic acid and amino acid sequences are provided as a feature of the present invention. This staphylococcal protein has a high degree of homology with eukaryotic MHC Class II antigens. Further analyses of the binding specificities of this protein reveal that it functionally resembles an MHC II antigen in that it binds synthetic peptides. Additionally, the present invention provides a vaccine and an in vivo vaccine against staphylococcal infections, and methods for using same.
摘要翻译：金黄色葡萄球菌可以结合许多不同的细胞外基质蛋白质。最近的研究表明，一种特定的葡萄球菌蛋白具有结合几种不同基质蛋白的能力。编码该葡萄球菌蛋白质的基因已经被克隆和测序，并且提供了核酸和氨基酸序列作为本发明的特征。这种葡萄球菌蛋白与真核MHC II类抗原具有高度的同源性。该蛋白质的结合特异性的进一步分析表明，它功能上类似于MHC II抗原，因为它结合合成肽。另外，本发明提供了针对葡萄球菌感染的疫苗和体内疫苗及其使用方法。

12. 发明申请

US20050287146A1 Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions 审中-公开
标题翻译：使用供体选择或供体刺激的免疫球蛋白组合物抑制念珠菌相关感染的方法
公开(公告)号：US20050287146A1
公开(公告)日：2005-12-29
申请号：US11016564
申请日：2004-12-20
申请人： Joseph Patti , John Vernachio , Yule Liu , Magnus Hook , Maria Bowden , Jenny Singvall
发明人： Joseph Patti , John Vernachio , Yule Liu , Magnus Hook , Maria Bowden , Jenny Singvall
IPC分类号： A61K39/00 , A61K39/395 , A61K39/40 , C07K16/12 , C07K16/14 , G01N33/569
CPC分类号： C07K16/1271 , A61K2039/505 , C07K16/14 , C07K2317/21 , G01N33/569 , G01N2333/40
摘要： A method for treating or preventing infections from yeast of the Candida species is provided wherein an immunoglobulin composition containing high titers of antibodies to staphylococcal adhesins ClfA and SdrG is administered in an amount effective to inhibit the growth and progression of Candidial infections. The compositions and methods of the present invention are advantageous in that they can be used to treat both staphylococcal and Candidial infections at the same time, and they are particularly effective in treating or preventing late-onset sepsis in neonates.
摘要翻译：提供了治疗或预防念珠菌种酵母感染的方法，其中以有效抑制候选感染的生长和进展的量施用含有高葡萄球菌粘附素ClfA和SdrG抗体滴度的免疫球蛋白组合物。本发明的组合物和方法的优点在于它们可用于同时治疗葡萄球菌和候选感染，并且它们在治疗或预防新生儿迟发性败血症方面特别有效。

13. 发明申请

US20130035476A1 CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A IN COMPLEX WITH FIBRINOGEN DERIVED PEPTIDE AND USES THEREOF 审中-公开
公开(公告)号：US20130035476A1
公开(公告)日：2013-02-07
申请号：US13605567
申请日：2012-09-06
申请人： Magnus Hook , Ya-Ping Ko , Emanuel Smeds , Vannakambadi K. Ganesh
发明人： Magnus Hook , Ya-Ping Ko , Emanuel Smeds , Vannakambadi K. Ganesh
IPC分类号： C07K16/12
CPC分类号： C07K14/75 , A61K38/00 , A61K38/363 , C07K14/31 , C07K16/1271 , C07K16/18 , C07K16/36 , G01N33/68 , G01N2333/31 , G01N2333/75
摘要： The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.

14. 发明申请

US20090203627A1 Specific binding sites in collagen for integrins and use thereof 有权
标题翻译：用于整联蛋白的胶原中的特异性结合位点及其用途
公开(公告)号：US20090203627A1
公开(公告)日：2009-08-13
申请号：US12383746
申请日：2009-03-26
申请人： Magnus Hook , Xuejun Xu , Jiyeun Kim
发明人： Magnus Hook , Xuejun Xu , Jiyeun Kim
IPC分类号： A61K38/08 , C12N15/63 , C12N5/10 , G01N33/566 , C07K7/06 , C07K19/00 , C12N5/06
CPC分类号： C07K14/00 , C07K7/06 , C07K14/78 , G01N33/566 , G01N33/6887 , G01N2333/70546 , G01N2333/78 , G01N2500/02
摘要： The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction.
摘要翻译：本发明鉴定了胶原结合整合蛋白I结构域中III型胶原中的高亲和力结合序列。本文提供了用于表征序列的方法，包含该新型序列的肽以及肽在使细胞粘附中的用途。本文还提供了鉴定特异性整联蛋白抑制剂，这些抑制剂的序列及其在抑制由于整合素 - 胶原相互作用可能引起的病理生理学病症中的用途的方法。

15. 发明申请

US20090162379A1 Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor 审中-公开
标题翻译：金黄色葡萄球菌SdrD蛋白抑制剂附着于细胞及其用途
公开(公告)号：US20090162379A1
公开(公告)日：2009-06-25
申请号：US12286586
申请日：2008-10-01
申请人： Magnus Hook , Elena M. Barbu
发明人： Magnus Hook , Elena M. Barbu
IPC分类号： A61K39/40 , G01N33/569 , G01N33/53 , C07K14/31 , A61K38/16 , C12N5/00 , C12N1/20 , C07K16/00 , A61P31/04
CPC分类号： G01N33/5044 , A61K2039/505 , C07K16/1271 , G01N2333/31
摘要： Provided herein is a method for identifying small molecule inhibitors of S. aureus SdrD protein attachment to a host cell receptor using a structural model of SdrD protein-receptor interaction. Also provided are the small molecule inhibitors so identified and synthetic small molecules effective to bind SdrD protein and/or the host cell receptor. In addition, antibodies directed against SdrD protein are provided. Further provided are methods of treating or preventing S. aureus associated lung infections and of inhibiting S. aureus adherence to a lung cell using the small molecules and antibodies described herein.
摘要翻译：本文提供了使用SdrD蛋白 - 受体相互作用的结构模型鉴定金黄色葡萄球菌SdrD蛋白附着于宿主细胞受体的小分子抑制剂的方法。还提供了如此鉴定的小分子抑制剂和有效结合SdrD蛋白和/或宿主细胞受体的合成小分子。此外，提供了针对SdrD蛋白的抗体。还提供了使用本文所述的小分子和抗体治疗或预防金黄色葡萄球菌相关肺感染和抑制金黄色葡萄球菌粘附至肺细胞的方法。

16. 发明申请

US20070092533A1 Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus 审中-公开
标题翻译：通过使用来自金黄色葡萄球菌的主要组织相容性复合物II类模拟蛋白（图蛋白）来预防T细胞介导的应答的方法
公开(公告)号：US20070092533A1
公开(公告)日：2007-04-26
申请号：US11643714
申请日：2006-12-22
申请人： Eric Brown , Lawrence Lee , Magnus Hook
发明人： Eric Brown , Lawrence Lee , Magnus Hook
IPC分类号： A61K39/02
CPC分类号： C07K14/31 , A61K38/00
摘要： A method of immunomodulating the T cell response in Staphylococcal bacteria is provided wherein an effective amount of the Map protein from Staphylococcus aureus is administered to a host to prevent or suppress the T cell response. The present method may be utilized with either the Map protein or an effective subdomain or fragment thereof such as the Map19 protein. The present invention is advantageous in that suppression or prevention of the T cell response in a host can prevent or ameliorate a wide variety of the pathogenic conditions such as toxic shock syndrome and other diseases associated with the T cell-mediated response caused by staphylococcal infection, and is particularly useful in cases where patients have had chronic or recurrent infections from S. aureus or other staphylococcal bacteria.
摘要翻译：提供了一种在葡萄球菌中免疫调节T细胞应答的方法，其中向宿主施用有效量的来自金黄色葡萄球菌的Map蛋白以预防或抑制T细胞应答。本方法可以与Map蛋白或有效亚结构域或其片段（如Map19蛋白）一起使用。本发明的优点在于，抑制或预防宿主中的T细胞应答可以预防或改善各种各样的致病性病症如毒性休克综合征和与由葡萄球菌感染引起的T细胞介导的应答相关的其它疾病，并且在患者具有来自金黄色葡萄球菌或其它葡萄球菌的慢性或反复感染的情况下特别有用。

17. 发明申请

US20060110380A1 Compositions for inhibiting thrombin-induced coagulation and methods of use 审中-公开
标题翻译：用于抑制凝血酶诱导的凝血的组合物及其使用方法
公开(公告)号：US20060110380A1
公开(公告)日：2006-05-25
申请号：US11010406
申请日：2004-12-14
申请人： Stacey Davis , Magnus Hook
发明人： Stacey Davis , Magnus Hook
IPC分类号： A61K38/48
CPC分类号： C07K14/31 , A61K38/164 , A61K38/482 , A61K2300/00
摘要： A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a fibrinogen-binding protein capable of binding at the N-terminal Bβ chain of fibrinogen, such as SdrG or Fbe, or their respective binding regions such as the A domain. In addition, compositions comprising effective amounts of the fibrinogen-binding proteins are also provided. The present anti-coagulation compositions have been shown to inhibit thrombin-induced fibrin clot formation by interfering with the release of fibrinopeptide B and the resulting anti-coagulation effects can be achieved without potential for causing or exacerbating unwanted side effects such as thrombocytopenia associated with prior art anticoagulants such as heparin.
摘要翻译：一种实现安全有效的治疗或预防潜在有害的血块，或在需要时抑制血液凝固的方法，例如在包括中风，心肌梗死，镰状细胞危象和静脉血栓形成在内的各种疾病状况下，是一种方法通过施用能够在纤维蛋白原的N-末端Bbeta链（例如SdrG或Fbe）或其各自的结合区域如A结构域结合的纤维蛋白原结合蛋白提供。此外，还提供了包含有效量的纤维蛋白原结合蛋白的组合物。已经显示本发明的抗凝组合物通过干扰纤维蛋白肽B的释放来抑制凝血酶诱导的纤维蛋白凝块形成，并且可以实现所得的抗凝血作用，而不会引起或加剧不期望的副作用，例如与先前相关的血小板减少症艺术抗凝剂如肝素。

18. 发明申请

US20050020491A1 Decorin proteoglycan inhibitor of fibrinogen blood clotting 有权
标题翻译： Decorin蛋白聚糖抑制剂的纤维蛋白原血液凝固
公开(公告)号：US20050020491A1
公开(公告)日：2005-01-27
申请号：US10898841
申请日：2004-07-26
申请人： Magnus Hook , Tracey Dugan
发明人： Magnus Hook , Tracey Dugan
IPC分类号： A61K38/17 , A61K47/48 , C07K14/47 , C07K14/705
CPC分类号： C07K14/4725 , A61K38/1709 , A61K47/61 , A61K2300/00
摘要： The present invention provides compositions and methods of inhibiting fibrin(ogen) clot formation by utilizing decorin proteoglycan as an anticoagulating and antithrombotic agent. The decorin proteoglycan comprises a decorin core protein or a fragment thereof covalently linked to a galactosaminoglycan polysaccharide. The decorin core protein acts as an anticoagulant and as a carrier for the delivery of an antithrombotic galactosaminoglycan to fibrinogen. Fibrin clotting is inhibited by the decorin proteoglycan in a concentration-dependent fashion.
摘要翻译：本发明提供了通过利用核心蛋白聚糖蛋白聚糖作为抗凝血和抗血栓形成剂来抑制纤维蛋白（ogen）凝块形成的组合物和方法。核心蛋白聚糖蛋白聚糖包含与半乳糖聚糖多糖共价连接的核心蛋白聚糖蛋白核心蛋白或其片段。核心蛋白聚糖核心蛋白质作为抗凝血剂和作为将抗血栓形成半乳糖聚糖交付给纤维蛋白原的载体。纤维蛋白凝块以浓度依赖性方式被核心蛋白聚糖蛋白聚糖抑制。

19. 发明申请

US20050002925A1 Surface proteins from gram-positive bacteria having highly conserved motifs and antibodies that recognize them 失效
标题翻译：来自具有高度保守基序的革兰氏阳性细菌的表面蛋白和识别它们的抗体
公开(公告)号：US20050002925A1
公开(公告)日：2005-01-06
申请号：US10911507
申请日：2004-08-05
申请人： Yi Xu , Magnus Hook
发明人： Yi Xu , Magnus Hook
IPC分类号： A61K39/00 , C07K14/31 , C07K14/315 , C07K16/12 , A61K39/395
CPC分类号： C07K14/3156 , A61K39/00 , A61K2039/505 , C07K14/31 , C07K14/315 , C07K16/1267 , Y10S930/29
摘要： Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAVVEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.
摘要翻译：提供了含有这些序列的分离的肽序列和蛋白质，其可用于预防和治疗由革兰氏阳性菌引起的感染。已经显示肽序列在革兰氏阳性细菌的表面蛋白中是高度保守的基序，并且这些共有序列包括氨基酸序列，例如LPXTG（SEQ ID NO：13），ALKTGKIDIIISGMTSTPERKK（SEQ ID NO：14），VEGAVVEKPVAEAYLKQN （SEQ ID NO：15）和EYAGVDIDLAKKIAK（SEQ ID NO：16）。由于高度保守的区域，包括这些序列的序列和蛋白质可用于产生能识别这些高度保守的基序和含有它们的蛋白质的抗体，因此可用于治疗或预防引起的广泛感染通过革兰氏阳性菌。

20. 发明申请

US20140163205A1 DESIGNER COLLAGENS AND USE THEREOF 有权
标题翻译： DESIGNER COLLAGENS及其使用
公开(公告)号：US20140163205A1
公开(公告)日：2014-06-12
申请号：US14095451
申请日：2013-12-03
申请人： Brooke H. Russell , Magnus Hook , Mariah S. Hahn , Elizabeth M. Cosgriff-Hernandez , Neungseon Seo , Marvin Xuejun Xu , Jose J. Rivera , Mary Beth Browning
发明人： Brooke H. Russell , Magnus Hook , Mariah S. Hahn , Elizabeth M. Cosgriff-Hernandez , Neungseon Seo , Marvin Xuejun Xu , Jose J. Rivera , Mary Beth Browning
IPC分类号： C07K14/78
CPC分类号： C07K14/78 , A61L15/325 , A61L26/0052 , A61L26/0066 , A61L26/008 , A61L26/0095 , A61L27/24 , A61L27/26 , A61L27/48 , A61L27/507 , A61L27/52 , A61L27/54 , A61L33/0064 , A61L33/062 , A61L2300/252 , A61L2300/42 , A61L2400/18 , A61L2430/02 , A61L2430/06 , A61L2430/34 , C07K2319/00 , C07K2319/33 , C07K2319/70 , C07K2319/74 , C07K2319/90 , C08G65/33327
摘要： The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.
摘要翻译：本公开提供合成胶原蛋白以及制备和使用合成胶原的方法，所述合成胶原包括促进伤口闭合的合成胶原，其包含分离和纯化的三螺旋骨架蛋白，其促进伤口闭合，其包括三螺旋骨架蛋白序列中的一个或多个改变，稳定分离和纯化的三螺旋骨架蛋白，不会破坏额外的胶原配体相互作用; 和一种或多种整联蛋白结合基序，其中所述分离和纯化的三螺旋骨架蛋白促进伤口闭合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式